Free Cash Flow Chart

View Free Cash Flow for OCUL.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow Chart
Start Trial

Historical Free Cash Flow Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 -255.10M
March 31, 2026 -240.94M
December 31, 2025 -216.89M
September 30, 2025 -199.44M
June 30, 2025 -179.37M
March 31, 2025 -148.43M
December 31, 2024 -135.96M
September 30, 2024 -114.06M
June 30, 2024 -90.59M
March 31, 2024 -87.11M
December 31, 2023 -76.32M
September 30, 2023 -77.70M
June 30, 2023 -78.49M
March 31, 2023 -67.79M
December 31, 2022 -63.32M
September 30, 2022 -59.99M
June 30, 2022 -59.29M
March 31, 2022 -68.10M
December 31, 2021 -66.74M
September 30, 2021 -57.46M
June 30, 2021 -58.07M
March 31, 2021 -52.81M
December 31, 2020 -54.40M
September 30, 2020 -68.56M
Date Value
June 30, 2020 -74.06M
March 31, 2020 -78.81M
December 31, 2019 -79.82M
September 30, 2019 -73.28M
June 30, 2019 -65.26M
March 31, 2019 -58.37M
December 31, 2018 -51.12M
September 30, 2018 -47.94M
June 30, 2018 -53.01M
March 31, 2018 -55.35M
December 31, 2017 -58.72M
September 30, 2017 -56.07M
June 30, 2017 -47.85M
March 31, 2017 -42.77M
December 31, 2016 -35.92M
September 30, 2016 -36.74M
June 30, 2016 -38.31M
March 31, 2016 -37.67M
December 31, 2015 -35.52M
September 30, 2015 -32.48M
June 30, 2015 -29.31M
March 31, 2015 -24.67M
December 31, 2014 -21.76M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
EyePoint, Inc. -271.28M
LENZ Therapeutics, Inc. -114.42M
Merck & Co., Inc. 16.06B
Theravance Biopharma, Inc. 53.73M
ANI Pharmaceuticals, Inc. 167.52M